PT  - JOURNAL ARTICLE
AU  - Wagner, Dirk
AU  - van Ingen, Jakko
AU  - Adjemian, Jennifer
AU  - Lange, Christoph
AU  - Prevots, D. Rebecca
AU  - Griffith, David
AU  - Gallagher, Jack
AU  - Gupta, Renu
AU  - Haworth, Charles
TI  - Annual prevalence and treatment estimates of nontuberculous mycobacterial pulmonary disease in Europe: A NTM-NET collaborative study
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P1067
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P1067.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P1067.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - Background: The prevalence of nontuberculous mycobacterial pulmonary disease (NTMPD) has been increasing in Europe; yet, comprehensive analyses and reliable estimates on treatment practices are lacking. We developed methods to assess annual prevalence, and used chart audits to evaluate treatment practices in 5 European countries (EU5): United Kingdom (UK), France, Germany, Italy, and Spain.Methods: NTMPD patients diagnosed annually was estimated by a 2-round Delphi method. A representative sample of physicians extracted treatment information from records of NTMPD patients with a confirmed diagnosis of Mycobacterium avium complex (MAC) or M. abscessus pulmonary disease.Results: Approximately 88% of all physicians contacted and 62% (446) with qualified patients participated. Pulmonologists made up the largest group of study physicians (Italy 17%, UK 38%). In EU5 most NTMPD patients are male (73%) and have a history of smoking (75%); COPD is the most common comorbidity (33%). MAC was the predominant species reported (79%). NTMPD estimated annual prevalence in EU5 ranged from 5.9 (Spain) to 6.5/100,000 (UK). A wide regional heterogeneity within countries was noted, particularly in France (Parisian region [13.6/100,000] vs Southwest region [1.3/100,000]). Logistic regression analysis showed that the decision to treat was most dependent on country (odds ratio = 6.2, Spain vs France) and severity of presenting symptoms (odds ratio = 1.9, severe vs mild).Conclusions: Annual prevalence of NTMPD is uniform on a per capita basis in EU5, but heterogeneous within different regions. The percentage of patients treated varies widely by country and severity.